<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34849577</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1477-4054</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Briefings in bioinformatics</Title><ISOAbbreviation>Brief Bioinform</ISOAbbreviation></Journal><ArticleTitle>Focused goodness of fit tests for gene set analyses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">bbab472</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bib/bbab472</ELocationID><Abstract><AbstractText>Gene set-based signal detection analyses are used to detect an association between a trait and a set of genes by accumulating signals across the genes in the gene set. Since signal detection is concerned with identifying whether any of the genes in the gene set are non-null, a goodness-of-fit (GOF) test can be used to compare whether the observed distribution of gene-level tests within the gene set agrees with the theoretical null distribution. Here, we present a flexible gene set-based signal detection framework based on tail-focused GOF statistics. We show that the power of the various statistics in this framework depends critically on two parameters: the proportion of genes within the gene set that are non-null and the degree of separation between the null and alternative distributions of the gene-level tests. We give guidance on which statistic to choose for a given situation and implement the methods in a fast and user-friendly R package, wHC (https://github.com/mqzhanglab/wHC). Finally, we apply these methods to a whole exome sequencing study of amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mengqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic and Computational Biology, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Statistical Genetics and Genomics, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelfman</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine, Columbia University, New York City, 10032, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins Moreno</LastName><ForeName>Cristiane Araujo</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine, Columbia University, New York City, 10032, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Janice M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine, Columbia University, New York City, 10032, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Institute of Genomic Medicine, Columbia University, New York City, 10032, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic and Computational Biology, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Statistical Genetics and Genomics, Duke University, Durham,27710, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brief Bioinform</MedlineTA><NlmUniqueID>100912837</NlmUniqueID><ISSNLinking>1467-5463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">gene set</Keyword><Keyword MajorTopicYN="N">genetic association</Keyword><Keyword MajorTopicYN="N">goodness-of-fit test</Keyword><Keyword MajorTopicYN="N">rare variants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>7</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34849577</ArticleId><ArticleId IdType="doi">10.1093/bib/bbab472</ArticleId><ArticleId IdType="pii">6444313</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>